Compare Albemarle Corp. (ALB) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Amylx Pharmaceuticals Inc — how do they compare? Albemarle Corp. trades at $128.3 (market cap $15.27B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B). The key difference: Albemarle Corp. is far larger — about 5.8× Amylx Pharmaceuticals Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALB | AMLX | |
|---|---|---|
Market Cap | $15.27B | $2.64B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $24.19 |
52-Week Low | $72.58 | $7.82 |
Enterprise Value | $17.75B | $2.39B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALB trades at $128.21, down 2.29% today, amid a mixed technical picture with bullish moving averages but overbought RSI signals. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.75, driven by improved lithium pricing and cost savings. Revenue for 2025 was $5.14B, though net income remained negative at -$510.63M. Analyst consensus is a Buy with a $184.50 price target, reflecting optimism for recovery.
Outlook is cautiously optimistic as lithium demand supports earnings growth, but Q3 guidance warns of sequential declines. Key risks include volatile lithium prices and execution challenges. The stock offers potential upside to analyst targets if operational improvements continue, but investors face margin pressure and macroeconomic headwinds.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
